Sufian K. M. Noor, Mosab Nouraldein Mohammed Hamad, Sarra Osman Bushara, Amel Abdalrhim Sulaiman3Mohamed Adil Yassen Ali4, Remaz Khalid Hassan Ahmed4, Almotasim Mohamed Aabdelmgid ElnaemaSamaher Mozamil Mohamed Abdelrahim2023-11-232023-11-232020https://ds.eaeu.edu.sd/handle/10.58971/435Agranulocytosis is an infrequent and serious side effect of antithyroid drugs characterized by a noticeable reduction in granulocyte and neutrophil count, it usually occurs within the first 2-3 months of treatment. There is a variety of mechanisms by which ATD can induce agranulocytosis, direct drug effects, and immunological mechanisms. We present 33 years old female attended Atbara teaching hospital who has developed agranulocytosis 2 weeks after starting ATD to treat relapsed Graves’ disease. What was unusual about this patient is that symptoms have occurred in a period less than 15 days of starting treatment and with a dose of 45 mg/day. The physician must educate the patient about the possibility of early onset of serious side effects of ATD and to seek medical advice as soon as possibleother